---
document_datetime: 2025-12-17 23:15:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/teriflunomide-viatris.html
document_name: teriflunomide-viatris.html
version: success
processing_time: 0.1175568
conversion_datetime: 2025-12-28 02:30:29.589322
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Teriflunomide Viatris (previously Teriflunomide Mylan)

[RSS](/en/individual-human-medicine.xml/67624)

##### Authorised

This medicine is authorised for use in the European Union

teriflunomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Teriflunomide Viatris (previously Teriflunomide Mylan)](#news-on)
- [More information on Teriflunomide Mylan](#more-information-on-teriflunomide-mylan-1632)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Teriflunomide Viatris is a medicine used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation attacks the protective covering (sheath) around nerves and damages the nerves themselves.

Teriflunomide Viatris is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).

Teriflunomide Viatris contains the active substance teriflunomide and is a 'generic medicine'. This means that Teriflunomide Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Aubagio. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Teriflunomide Viatris used?

Teriflunomide Viatris can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the management of MS.

Teriflunomide Viatris is available as tablets to be taken once a day.

For more information about using Teriflunomide Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Teriflunomide Viatris work?

In multiple sclerosis, the immune system (the body's natural defences) attacks the protective sheath around the nerves and the nerves themselves in the brain and spinal cord. The active substance in Teriflunomide Viatris, teriflunomide, blocks an enzyme called dihydroorotate dehydrogenase which is necessary for cells to multiply. The exact way teriflunomide works in MS is not known but it is thought to reduce the number of T lymphocytes which form part of the immune system and are involved in the inflammation process. With fewer T lymphocytes, there is less inflammation, helping to control the symptoms of MS.

## How has Teriflunomide Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Aubagio, and do not need to be repeated for Teriflunomide Viatris.

As for every medicine, the company provided studies on the quality of Teriflunomide Viatris. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Teriflunomide Viatris?

Because Teriflunomide Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Teriflunomide Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Teriflunomide Viatris has been shown to have comparable quality and to be bioequivalent to Aubagio. Therefore, the Agency's view was that, as for Aubagio, the benefits of Teriflunomide Viatris outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Teriflunomide Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Teriflunomide Viatris have also been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Aubagio, such as educational material for healthcare professionals and a patient card with key safety information, also apply to Teriflunomide Viatris where appropriate.

As for all medicines, data on the use of Teriflunomide Viatris are continuously monitored. Suspected side effects reported with Teriflunomide Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Teriflunomide Viatris

Teriflunomide Mylan received a marketing authorisation valid throughout the EU on 9 November 2022.

The name of the medicine was changed to Teriflunomide Viatris on 15 October 2024.

Teriflunomide Viatris : EPAR - Medicine overview

Reference Number: EMA/536291/2024

English (EN) (146.56 KB - PDF)

**First published:** 22/11/2022

**Last updated:** 28/01/2025

[View](/en/documents/overview/teriflunomide-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-697)

български (BG) (154.36 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/bg/documents/overview/teriflunomide-viatris-epar-medicine-overview_bg.pdf)

español (ES) (146.78 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/es/documents/overview/teriflunomide-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (167.63 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/cs/documents/overview/teriflunomide-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (145.5 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/da/documents/overview/teriflunomide-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.84 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/de/documents/overview/teriflunomide-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (142.9 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/et/documents/overview/teriflunomide-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (171.37 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/el/documents/overview/teriflunomide-viatris-epar-medicine-overview_el.pdf)

français (FR) (147.76 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/fr/documents/overview/teriflunomide-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (164.58 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/hr/documents/overview/teriflunomide-viatris-epar-medicine-overview_hr.pdf)

italiano (IT) (144.5 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/it/documents/overview/teriflunomide-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (176.81 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/lv/documents/overview/teriflunomide-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.49 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/lt/documents/overview/teriflunomide-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (167.85 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/hu/documents/overview/teriflunomide-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (169 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/mt/documents/overview/teriflunomide-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (146.52 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/nl/documents/overview/teriflunomide-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (171.37 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/pl/documents/overview/teriflunomide-viatris-epar-medicine-overview_pl.pdf)

português (PT) (147.06 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/pt/documents/overview/teriflunomide-viatris-epar-medicine-overview_pt.pdf)

română (RO) (163.96 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/ro/documents/overview/teriflunomide-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (166.95 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/sk/documents/overview/teriflunomide-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (163.74 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/sl/documents/overview/teriflunomide-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (143.38 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/fi/documents/overview/teriflunomide-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (143.84 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

28/01/2025

[View](/sv/documents/overview/teriflunomide-viatris-epar-medicine-overview_sv.pdf)

Teriflunomide Mylan : EPAR - Risk management plan summary

English (EN) (146.41 KB - PDF)

**First published:** 22/11/2022

[View](/en/documents/rmp-summary/teriflunomide-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Teriflunomide Viatris : EPAR - Product information

English (EN) (253.62 KB - PDF)

**First published:** 22/11/2022

**Last updated:** 11/12/2025

[View](/en/documents/product-information/teriflunomide-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-283)

български (BG) (692.31 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/bg/documents/product-information/teriflunomide-viatris-epar-product-information_bg.pdf)

español (ES) (436.58 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/es/documents/product-information/teriflunomide-viatris-epar-product-information_es.pdf)

čeština (CS) (513.62 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/cs/documents/product-information/teriflunomide-viatris-epar-product-information_cs.pdf)

dansk (DA) (374.84 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/da/documents/product-information/teriflunomide-viatris-epar-product-information_da.pdf)

Deutsch (DE) (454.18 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/de/documents/product-information/teriflunomide-viatris-epar-product-information_de.pdf)

eesti keel (ET) (499.42 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/et/documents/product-information/teriflunomide-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (387.18 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/el/documents/product-information/teriflunomide-viatris-epar-product-information_el.pdf)

français (FR) (522.64 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/fr/documents/product-information/teriflunomide-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (620.44 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/hr/documents/product-information/teriflunomide-viatris-epar-product-information_hr.pdf)

íslenska (IS) (372.46 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/is/documents/product-information/teriflunomide-viatris-epar-product-information_is.pdf)

italiano (IT) (531.9 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/it/documents/product-information/teriflunomide-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (436.07 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/lv/documents/product-information/teriflunomide-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (459.77 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/lt/documents/product-information/teriflunomide-viatris-epar-product-information_lt.pdf)

magyar (HU) (744.04 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/hu/documents/product-information/teriflunomide-viatris-epar-product-information_hu.pdf)

Malti (MT) (694.34 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/mt/documents/product-information/teriflunomide-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (585.68 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/nl/documents/product-information/teriflunomide-viatris-epar-product-information_nl.pdf)

norsk (NO) (392.78 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/no/documents/product-information/teriflunomide-viatris-epar-product-information_no.pdf)

polski (PL) (674.19 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/pl/documents/product-information/teriflunomide-viatris-epar-product-information_pl.pdf)

português (PT) (520.22 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/pt/documents/product-information/teriflunomide-viatris-epar-product-information_pt.pdf)

română (RO) (717.63 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/ro/documents/product-information/teriflunomide-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (689.29 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/sk/documents/product-information/teriflunomide-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (387.27 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/sl/documents/product-information/teriflunomide-viatris-epar-product-information_sl.pdf)

Suomi (FI) (543.75 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/fi/documents/product-information/teriflunomide-viatris-epar-product-information_fi.pdf)

svenska (SV) (383.72 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

11/12/2025

[View](/sv/documents/product-information/teriflunomide-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000316808 11/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Teriflunomide Viatris : EPAR - All authorised presentations

English (EN) (12.21 KB - PDF)

**First published:** 22/11/2022

**Last updated:** 17/10/2024

[View](/en/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-352)

български (BG) (73.18 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/bg/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (9.56 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/es/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (57.17 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/cs/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22.88 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/da/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (63.35 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/de/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.56 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/et/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.76 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/el/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (78.08 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/fr/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (35.31 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/hr/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.56 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/is/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (51.52 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/it/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (54.14 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/lv/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (54.15 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/lt/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (37.01 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/hu/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (54.22 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/mt/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.71 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/nl/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (54.38 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/no/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (35.83 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/pl/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.64 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/pt/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.13 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/ro/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (65.07 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/sk/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (58.45 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/sl/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (70.69 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/fi/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.23 KB - PDF)

**First published:**

22/11/2022

**Last updated:**

17/10/2024

[View](/sv/documents/all-authorised-presentations/teriflunomide-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Teriflunomide Viatris (previously Teriflunomide Mylan) Active substance teriflunomide International non-proprietary name (INN) or common name teriflunomide Therapeutic area (MeSH) Multiple Sclerosis, Relapsing-Remitting Anatomical therapeutic chemical (ATC) code L04AK02

### Pharmacotherapeutic group

- Immunosuppressants
- Dihydroorotate dehydrogenase (DHODH) inhibitors

### Therapeutic indication

Teriflunomide Mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight &gt; 40 kg) with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 of the SmPC for important information on the population for which efficacy has been established).

## Authorisation details

EMA product number EMEA/H/C/005962

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin Dublin 15 Ireland

Opinion adopted 15/09/2022 Marketing authorisation issued 09/11/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Teriflunomide Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (127.9 KB - PDF)

**First published:** 11/12/2025

[View](/en/documents/procedural-steps-after/teriflunomide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Teriflunomide Viatris : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (152.49 KB - PDF)

**First published:** 16/01/2023

**Last updated:** 11/12/2025

[View](/en/documents/procedural-steps-after/teriflunomide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Teriflunomide Mylan-H-C-PSUSA-00010135-202309 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/240603/2024

English (EN) (141.58 KB - PDF)

**First published:** 24/07/2024

[View](/en/documents/scientific-conclusion/teriflunomide-mylan-h-c-psusa-00010135-202309-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Teriflunomide Mylan : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/792181/2022

English (EN) (699.99 KB - PDF)

**First published:** 22/11/2022

[View](/en/documents/assessment-report/teriflunomide-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Teriflunomide Mylan

Adopted

English (EN) (116.95 KB - PDF)

**First published:** 16/09/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-teriflunomide-mylan_en.pdf)

#### News on Teriflunomide Viatris (previously Teriflunomide Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

#### More information on Teriflunomide Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-754)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 11/12/2025

## Share this page

[Back to top](#main-content)